Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 24, 17489, Greifswald, Germany
Lariam 250mg tablets.
| Pharmaceutical Form |
|---|
|
Tablet. White to off-white cylindrical biplanar tablets, cross scored and imprinted with LA-RI-AM-CP on one face. |
Each tablet contains 250 mg mefloquine (as 274.09 mg mefloquine hydrochloride).
Each tablet contains 50.61 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Mefloquine |
Mefloquine acts on and destroys the asexual intraerythocytic forms of the human malaria parasites: Plasmodium falciparum, P. vivax. P. malariae and P. ovale. It is effective in the treatment and prophylaxis of malaria. |
| List of Excipients |
|---|
|
Microcrystalline cellulose |
Aluminium foil packs containing 8 tablets.
CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 24, 17489, Greifswald, Germany
PL 27041/0012
5 October 1989 / 1 February 2004
| Drug | Countries | |
|---|---|---|
| LARIAM | Austria, Estonia, Finland, France, Malta, Netherlands, United Kingdom, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
